Haisco Group wins clinical trial nods for four innovative drugs

Haisco Pharmaceutical Group's subsidiary, Shanghai Haisheng Nuo Pharmaceutical Technology Co., Ltd., has obtained clinical trial approval for four innovative drugs: HSK45019 tablets, HSK50042 tablets, HSK55718 injectable, and HSK36357 capsules. These approvals were granted by the National Medical Products Administration, following an application filed in October 2025.

HSK45019 tablets are intended for inflammatory bowel disease, HSK50042 tablets for respiratory system diseases, and HSK55718 injectable for acute pain. HSK36357 capsules are slated for the treatment of muscular dystrophy. All four drugs are classified as Class 1 chemical drugs under the "Chemical Drug Registration Classification and Application Material Requirements" issued by the NMPA.

The company highlighted that these approvals signify compliance with drug registration requirements, allowing the initiation of clinical trials. The announcement also included a risk warning, noting that innovative drug development is a lengthy, complex, and high-risk process subject to uncertainties.